NasdaqCM:TGTXBiotechs
TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives
Intro
TG Therapeutics (TGTX) just closed out FY 2025 with Q4 revenue of US$192.6 million and basic EPS of US$0.16, alongside trailing twelve month revenue of US$616.3 million and EPS of US$3.10. Over the past couple of years, the company has reported revenue increasing from US$83.9 million in Q3 2024 to US$192.6 million in Q4 2025. Quarterly basic EPS has ranged from US$0.03 in Q1 2025 to US$2.69 in Q3 2025 and US$0.16 in the latest quarter, framing this release as a check-in on how durable...